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Objective: To evaluate the effects of the inhaled flunisolide upon the strength and
endurance of the respiratory and peripheral muscles of normal subjects.
Design: A randomized, double blind and placebo-controlled study.
Setting: A university-affiliated teaching hospital.
Participants: Thirteen normal volunteers selected from a graduation course.
Intervention: Subjects were randomly allocated to receive a placebo or corticosteroid
(flunisolide) to be inhaled twice a day for 4 weeks. After 2 weeks of a washout period,
subjects who were receiving the placebo, received flunisolide and vise versa for another
4-week period.
Measurements and results: Spirometry was used to define the volunteers as being normal
in terms of pulmonary function. During the study, subjects performed tests of respiratory
muscle function (strength and endurance), measurements of handgrip strength and
endurance and anthropometric measurements. Muscle strength was measured each week
while muscle endurance was measured every 2 weeks. There was no significant difference
in the maximal inspiratory and expiratory pressure and handgrip strength during weeks 1–4
when the subjects used either flunisolide or placebo. However, we observed an increase in
the endurance time of the respiratory and handgrip muscles in the 4th week of both
flunisolide and placebo use, what may be considered due to a learning effect.Published by Elsevier Ltd.
ce; AMC: arm muscular circumference; BMI: body mass index; FEV1: forced expiratory volume in the 1 s;
ce; PEmax: maximal expiratory pressure; PImax: maximal inspiratory pressure; SD: standard deviation;
ness
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acute or clinically perceived effect in the peripheral or respiratory muscles.
& 2007 Published by Elsevier Ltd.Introduction
Steroid-induced myopathy is defined as a muscular
weakness which occurs in subjects being treated with
corticosteroids without any other previous neuromuscular
disease.1 In a study of two groups of patients with
chronic obstructive pulmonary disease (COPD), comparable
in respect to their degree of bronchial obstruction, sex
and age, Decramer and Koenraad2 demonstrated that
the group with corticosteroid myopathy presented
accentuated weakness of the quadriceps and general
muscular atrophy. Muscular biopsy demonstrated that
the atrophy was predominant in the types IIa and IIb
fibers.
Studies in animals have demonstrated that the decrease
in diaphragmatic force is directly proportional to the loss of
its muscular mass and to alterations in the energy produc-
tion metabolism.3–5 In patients with asthma or collagen
diseases, treatment with corticosteroids reduces the muscle
strength.6
Due to the systemic effects of the systemic use of
glucocorticoids, both in the muscles and other organs,
inhalatory administration has been considered as ideal for
delivering these medications in patients with chronic
obstruction airflow. This form of application allows the
administration of relatively small doses of the drug, which
produce the same beneficial effects in the airways as the
systemic use of corticosteroids.7
Although we have already demonstrated that inhaled
flunisolide does not cause alterations in the bone
and suprarenal metabolisms of asthmatics,8 others have
demonstrated that a systemic absorption of the inhaled
corticosteroid may occur with the subsequent appearance
of adverse effects.9 These effects may be dependent
upon the dose, the sensitivity of the organ or of the
individual. In COPD patients, for instance, it has been
shown that inhaled triamcinolone (1200mcg dose) decreases
the bone mineral density faster than with the use of
placebo.10 Skin bruises after using inhaled fluticasone
(1000mcg/day) has also been referred as a side
effect in COPD patients which demonstrate the systemic
absorption of inhaled corticosteroid.11 Currently high
doses of inhaled corticosteroids have been proposed for
a group of COPD patients with stable disease.10 This
could have a negative systemic effects on these COPD
patients. However, as far as we know, there is no
any controlled, randomized double blind study that has
analyzed the possibility of an adverse effect with the
inhalation of corticosteroid upon the respiratory or periph-
eral muscles.
The objective of this study was to analyze the effects of
topical flunisolide upon the respiratory and peripheral
muscles function of normal subjects.Patients and methods
Sample size considerations
A sample size of 12 patients would permit a power of 80% to
detect a clinically relevant treatment difference on PImax
(assuming the true difference between the treatments being
25 cm H2O) with a two-sided 5% significance level (P
value).12–14 The within-patient standard deviation of the
maximal inspiratory pressure for this estimate was 20.0 cm
H2O, according to the Brazilian reference values.
15Volunteers
Thirteen male post-graduate students were recruited for the
study with the following criteria: normal spirometry, no
history or evidence of respiratory, cardiac, allergic, neuro-
muscular, rheumatological or endocrinal disease and no
upper respiratory infections or use of any medication during
the 3 weeks proceeding the study.Study plan
A randomized, double blind, cross-over and placebo-
controlled study was carried out. Subjects were randomly
allocated to receive an inhaled placebo or the inhaled
corticosteroid (flunisolide, 1000mcg/day, divided in two
doses) for 4 weeks. The metered dose inhalers had exactly
the same appearance, except by an identification code,
which was kept in secret to avoid bias until the end of the
data collection and analysis period. After a 2-week washout
period the process was reinitiated, but in reverse, and the
placebo aerosol was used for a further 4 weeks. Before the
initiation of the study, the subjects performed spirometry
and measurements of strength and endurance of the
respiratory and handgrip muscles as well as a nutritional
evaluation (body mass index, triceps cutaneous skinfold
thickness and arm muscle circumference). The subjects
signed an informed consent form and the study was
approved by the Committee of Research Ethics of the
Intuition.Spirometry
Spirometry was performed to define the volunteers as
normal in terms of their pulmonary function. A VITATRACE
VT 130SL spirometer (Brazil)) was utilized following the
criteria of the American Thoracic Society.16
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Respiratory muscle strength was assessed by measuring the
maximal inspiratory and maximal expiratory pressures (PImax
and PEmax, respectively) generated against an occluded
airway at the functional residual capacity with the
individual in a sitting position and using a nasal clip. We
used an aneroid manovacuometer calibrated in cm H2O
(IMEBRASs, Brazilian Industry). For both the PImax and the
PEmax, the subject maintained the contraction for 1 s and the
highest value obtained (among 10 tries) was considered
as the maximum. For the inspiratory measurement, the
apparatus contained a 1mm-hole to avoid closure of
the glottis. Cheek compression was performed during the
expiratory maneuver. To train the subject in the maneuver
and to evaluate the reproducibility of the measurement, the
PImax and the PEmax were measured 10 times with an 1min
rest interval among them on 3 consecutive days. During the
4 weeks of the study with each aerosol this measurement
was performed weekly with 5 measurements.
Respiratory muscle endurance
Respiratory muscle endurance was measured with a T piece
adapted to the aneroid manovacuometer, with the subject
inspiring through an orifice and generating a pressure
corresponding to 80% of his PImax in each respiratory cycle.
The maximum time, in seconds, that the individual could
tolerate performing 20 inspirations per minute was con-
sidered as the endurance measurement. This measurement
was taken before the use of the flunisolide or placebo
aerosol and in the second and fourth weeks of their use.
Handgrip strength
A dynamometer, calibrated in Kgforce (KgF) was utilized for
the measurement of handgrip strength. This measurement
was performed for 3 consecutive days with 5 reproductive
forces to find the best value. The subject remained seated,
with the forearm rested on the arm of a chair and the fist
supported by the opposite hand; the maximum voluntary
handgrip strength maneuver had to be maintained for 1 s.
This measurement was carried out again on the same days as
the respiratory muscular strength measurements.
Handgrip endurance
This maneuver was performed in the same position as
described above. The maximum time, in seconds, that the
individual could tolerate performing 20 handgrip movements
per minute, reaching 50% of the maximum voluntary
strength was considered to be the endurance time. This
maneuver was repeated on the same days as the respiratory
muscle endurance measurements.
Nutritional evaluation
The body mass index (BMI) was obtained by dividing the
subject’s weight by the height squared (kg/m2); arm
circumference (AC): the circumference of the non-dominantarm was measured, in centimeters, at the mid point of the
arm parallel to the body. The middle point of the arm was
determined as the half-way point between the acromion and
the olecranon; arm muscular circumference (AMC): the AMC
was calculated using the following equation, in centimeters:
AMC ¼ AC(3.1416 triceps cutaneous skinfold thickness);
Triceps cutaneous skinfold thickness (TCST)
The adipose tissue was pinched between the thumb and the
index finger at the mid point of the arm and the
measurement was taken, in mm, with a CESCORFs Skinfold
Instrument (Japanese Industry). The measurement was
repeated at least three times and variations greater than
4mm were not accepted. The median value was considered
as the TCST.
The nutritional evaluation measurements were performed
before the study and after 1 month of aerosol therapy both
for the placebo and flunisolide treatments.
Statistical analysis
Data were reported as mean7SD. For data analyses, the
following non-parametric tests were applied: Analysis of
variance by the Friedman test to compare the PImax, PEmax
and handgrip strength variables on the 3 consecutive days of
pre-randomized measurements and to compare the respira-
tory muscle and handgrip strength and endurance variables
at the different times of the study (0–4 weeks and 0, 2 and 4
weeks, respectively); the Wilcoxon test for two non-
independent samples was used to compare, for each
subject, the pre-placebo and pre-medication parameters.
In all the tests Pp0.05 was considered significant.
Results
Thirteen volunteers completed the respiratory muscle
strength and endurance measurements; one volunteer could
not perform the measurements of the handgrip strength and
endurance and arm muscular circumference due to the
immobilization of his arm following a wrist fracture during a
car accident. So those measurements were performed in 12
volunteers.
The mean7SD of subjects age (years), weight (kg) and
height (cm) were, respectively, 30.177.7, 75.2711.4 and
17374.3. The mean7SD (% predicted) of forced vital
capacity (FVC) (L), forced expiratory volume in the 1 s
(FEV1) (L) and FEV1/FVC 5.3+0.7(100.4%), 4.3+0.6 (98.4%)
and 84.3+5.4%, respectively.
The respiratory muscle strength measurements taken
on 3 consecutive days before the start of the study were
reproducible with no significant differences (PImax ¼
182.178.0 cm H2O 182.979.2 cm H2O 180.479.7 cm
H2O, respectively; PEmax ¼ 140.0722.5 cm H2O 140.87
24.9 cm H2O 142.3726.2 cm H2O, respectively) (Fig. 1).
The same was observed for the handgrip strength
(4.670.7 KgF 4.770.8 KgF 4.870.9 KgF, on the 1st, 2nd
and 3rd days, respectively; Fig. 2).
The statistical analysis showed that the individuals
presented no difference on the values pre-placebo and
pre-flunisolide periods for all variables studied (BMI ¼
24.870.9 kg/m2 24.870.9 kg/m2; PImax ¼ 178.5719.6 cm
ARTICLE IN PRESS
Strength and endurance of the respiratory and handgrip muscles 1597H2O 182.3720.3 cm H2O; PEmax ¼ 148.9722.6 cm H2O
146.5727.6 cm H2O; handgrip force ¼ 5.070.3 KgF 4.97
0.3 KgF; AMC ¼ 27.471.3mm 27.471.8mm; respiratory
muscle endurance ¼ 1205.57957.2 s 1161.271034.7 s and
handgrip endurance ¼ 666.77274.7 s 674.17330.9 s, re-
spectively). This allowed us to join all patients into two
groups, placebo and flunisolide.
There was no decrease in the PImax and PEmax during
weeks 1–4 when the subjects used flunisolide and when they
used placebo aerosol (Table 1).Figure 1 Mean of PImax (white) and PEmax (black) taken in
three consecutive days, as basal values, in 13 normal subjects.
Figure 2 Mean of handgrip strength in three consecutive days,
as basal values, in 13 normal subjects.
Table 1 The inspiratory and expiratory pressures during the w
Week
0 1 2
Placebo Flunisolide Placebo Flunisolide Placebo
PImax (cm
H2O)
178.5719.6 182.3720.0 185.8711.0 185.8712.2 183.571
PEmax (cm
H2O)
148.9722.6 146.5727.6 149.2723.2 142.7727.5 147.772
The values are expressed as mean7SD.The handgrip strength was used to evaluate the periph-
eral skeletal muscles and to act as a control for the
respiratory muscles. No statistically significant changes
were seen in the handgrip force during the utilization
of flunisolide (4.970.8 KgF 4.970.8 KgF 5.170.8 KgF
5.171 KgF) or placebo (5.171 KgF 4.971 KgF 5.27
0.9 KgF 5.371.2 KgF) during weeks 1, 2, 3 and 4,
respectively (Fig. 3).
The respiratory muscle endurance recorded during
the use of placebo and flunisolide are demonstrated in
Fig. 4. There was a progressive increase in the endurance
time during the use of both flunisolide (1161.27886.9 s
1191.67959.1 s 1451.47924.1 s) and placebo (1210.27
886.9 s 1228.87813.7 s 1488.571052.3 s) in weeks 0, 2
and 4, respectively, but this increase was just statistically
significant on the 4th week of the flunisolide group. A similar
effect was seen with the handgrip muscle endurance.
Although there was an increase in the time from week
0 to weeks 2 and 4, both in the flunisolide group
(6747305.1 s 715.97283.2 s 880.87357.7 s) and in the
placebo group (666.77252.7 s 718.47362 s 821.57
393 s), respectively, this increase was just statistically
significant in the flunisolide group (Fig. 4).
No alterations in the BMI or the AMC were seen follow-
ing the administrations of the placebo (BMI ¼ 24.87
3.4 kg/m2 24.973.0 kg/m2; AMC ¼ 27.471.3mm 26.9
71.3mm) or flunisolide (BMI ¼ 24.872.9 kg/m2 24.37
3 kg/m2; AMC ¼ 27.371.9mm 26.971.9mm), respec-
tively (P ¼ NS).hole study.
3 4
Flunisolide Placebo Flunisolide Placebo Flunisolide
4.6 181.9719.3 187.777.7 183.9716.1 186.2710.2 185.4713.7
0.3 144.6728.6 143.1723.7 144.2725.9 145.0722.5 139.6723.1
Figure 3 Mean (+ SD in bars) of handgrip strength during the
use of 1000mcg inhaled flunisolide (~), and placebo (J), for 1
month, in 12 normal subjects.
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Figure 4 Respiratory and handgrip muscles endurance time
(seconds) during the use of 1000mcg inhaled flunisolide (~),
and placebo (J), at weeks 0, 2 and 4.
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The aim of this study was to determine if the use of inhaled
flunisolide for 1 month would bring any alteration in the
strength and/or endurance properties of the respiratory
muscles and the peripheral muscles (represented, in this
study, by the handgrip muscles). Although corticosteroid
inhalation has been used for many years, we do not know of
any study about the adverse effects of this form of
administration upon the respiratory and peripheral muscles.
Due to the adverse effects the use of systemic glucocorti-
coids may bring, the inhalatory via has been often used for
their administration and is considered to be an alternative
method for supplying this medication for patients with
airflow obstruction. Inhaled corticosteroids produce the
desired anti-inflammatory effect in the airways, with
minimal systemic absorption.17 However patients with
severe obstruction, may require the use of high doses of
corticosteroids, which may increase the potential for
adverse effects systemic occurrence.
One of the undesirable effects of systemic glucocorticoids
is that they can cause motor dysfunction as a consequence
of the direct effects of the steroids upon the skeletal
muscles which include the reduction of muscular mass,5 loss
of myofibril protein and susceptibility to fatigue.18–20 The
extent a muscle is affected, varies according to the
composition of its fibers21 which may be variable in animal
and human muscles, depending on the predominance of
Type I or Type II fibers.22 In steroid myopathy, the Type II
fibers are the most affected.23
The locomotor muscles with predominantly postural
function seem to be less susceptible to corticosteroid-
induced myopathy.24 Based on these considerations, it would
be expected that the red skeletal muscle fibers with
continuous activity should be more resistant to steroid-
induced myopathy. However a study on the costal diaphragm
of rats demonstrated that the sarcoplasmic reticulum and
myofibril proteins were reduced by the use of high doses of
prednisolone without any significant alteration in the fibers
of the vertebral portion.25 This more intense lesion in the
costal section may decrease the respiratory muscle endur-
ance, as this muscle has a predominance of slow contraction
fibers.26 We have evaluated both the strength and endur-
ance of the respiratory and handgrip muscles, based uponthe fact that the respiratory muscles predominantly present
characteristics of endurance and the handgrip muscles have
a greater predominance of force fibers.
A dose of 1000mcg of flunisolide was chosen in the study
as this is considered to be a moderate-to-high dose and it is
usually prescribed in daily practice; in addition, previous
studies indicate that low or moderate doses of oral
corticoidsteroid have little or no effect upon the ventilatory
muscular performance.27 Thus, the possibility that the
respiratory muscular strength may be compromised by small
doses using the inhalatory via could be discarded.
The primary finding of our study was the fact that there
was no decrease in the respiratory muscle force (PImax and
PEmax) after the use of flunisolide for 1 month. This study had
an 80% power to detect a difference of 25 cm H2O or more in
the PImax between the treatments. Such difference can be
assumed to be clinically important, because an increase of
such amount can be related to structural respiratory fiber
muscles changes in COPD patients,14 as well as patient-
oriented outcomes, such as a decrease in dyspnea sensation
and increase in exercise tolerance and quality of life.13 It
has to be considered, however, that on the basis of this study
design a steroid-induced myopathy by inhaled corticoster-
oids can not be fully excluded and further studies are
required , specially addressing a longer treatment time.
Study limitations
Respiratory and handgrip muscles endurance measurements
variation: the experimental design included multiple mea-
surements of the endurance muscle properties in the period
following randomization and treatment arms. This could
probably induce a training effect28 and neutralize any
weakening property of the inhaled fluticasone. However,
for the respiratory muscle endurance test, previous studies
have defended the idea that a learning period, consisting of
1–3 tests, should be used to obtain reproducible results.29–31
Indeed, the finding of greater respiratory muscle endurance
at the end of the treatment period may reflect a training
effect due to the multiple measurements carried out during
the study period. The analysis of the response to nerve
stimulation would be indicated to exclude the possibility of
a learning effect, or a submaximal effort at the beginning of
the study. However, this outcome measurement was not
considered before the beginning of the study, and was not
performed. In addition, there was an inadequate sample size
to detect differences for the peripheral and respiratory
endurance muscle parameters, because of the wide spread
of these data (SD values of 90%, on average).
Subject’s adherence and study design
Some criticisms can be made regarding the cross—over
design of this study, because of the risk of carry-over effects
of the first treatment in the second treatment. However, an
accepted wash out period of 2 weeks (to minimize the
effects of inhaled corticosteroids) was adopted to avoid the
carry-over risk. In addition, the measurements before
the two periods of placebo or flunisolide showed no
difference at all, proving that no carry over effect has
happened. Despite all subjects were graduate students and
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adherence to the protocol, there were no objective
measurements to assess adequate adherence.
Maximal inspiratory and expiratory values: in some
subjects, the baseline PEmax was inferior to the PImax values.
This fact is not usual, and this finding could be possibly
explained by an uncomfortable sensation when performing
the PEmax measurement due to the Valsalva phenomenon.
However, this pattern was maintained during the study
(which showed an increase in PEmax and PImax values), and
the experience in performing the static pressures, as well as
motivation or other confounding factors could then be
excluded.
Our results indicate that a high dose of inhaled
corticosteroid during a short period (1 month) has no effect
upon the strength and endurance of the respiratory and
handgrip muscles. These results may not be extrapolated to
other doses and longer treatment duration. New studies are
necessary to determine whether subjects with chronic
respiratory disease reproduce this finding.References
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